<code id='BBE6B9D54F'></code><style id='BBE6B9D54F'></style>
    • <acronym id='BBE6B9D54F'></acronym>
      <center id='BBE6B9D54F'><center id='BBE6B9D54F'><tfoot id='BBE6B9D54F'></tfoot></center><abbr id='BBE6B9D54F'><dir id='BBE6B9D54F'><tfoot id='BBE6B9D54F'></tfoot><noframes id='BBE6B9D54F'>

    • <optgroup id='BBE6B9D54F'><strike id='BBE6B9D54F'><sup id='BBE6B9D54F'></sup></strike><code id='BBE6B9D54F'></code></optgroup>
        1. <b id='BBE6B9D54F'><label id='BBE6B9D54F'><select id='BBE6B9D54F'><dt id='BBE6B9D54F'><span id='BBE6B9D54F'></span></dt></select></label></b><u id='BBE6B9D54F'></u>
          <i id='BBE6B9D54F'><strike id='BBE6B9D54F'><tt id='BBE6B9D54F'><pre id='BBE6B9D54F'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:4

          What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a singular regulator?

          We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We explain the debate over Vertex Pharmaceuticals’ novel pain drug, whose success in clinical trials comes with a sizable caveat. We also talk about the latest news in the life sciences, including an epitaph for Aduhelm and the retirement of an FDA icon.

          advertisement

          For more on what we cover, here’s the news on Vertex; here’s more on Aduhelm; here’s the exit interview with Janet Woodcock; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

          Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

          And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

          advertisement

          explore

          Medical records are filled with copy
          Medical records are filled with copy

          AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

          read more
          With psoriasis trial ahead, Alumis raises $259 million
          With psoriasis trial ahead, Alumis raises $259 million

          Aclose-upofpsoriasisonahand.AdobeSanFranciscostartupAlumisInc.hasraised$259millioninabidtobestbigpha

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          Readout Newsletter: Geron, Novo Nordisk, WuXi updates

          KayanaSzymczakforSTATWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiote